AOP-Wiki

API

All Key Events

Showing 1226 to 1250 of 1921 Key Events

ID	Title	Event Component Count	Biological Organization	Created At	Last Updated	AOPs

1139	Increased, water retention in foot Short Name Increased, water retention in foot	0	Organ	Nov 29, 2016	Dec 3, 2016	97: 5-hydroxytryptamine transporter (5-HTT; SERT) inhibition leading to population decline
1138	Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP Short Name	2	Molecular	Nov 29, 2016	Sep 16, 2017	187: Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage
1137	Under carboxylation of osteocalcin, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone Short Name	0		Nov 29, 2016	Nov 29, 2016	None
1136	Impaired recruitment , Population trajectory Short Name	1	Population	Nov 29, 2016	Dec 3, 2016	187: Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage
1135	Reduced fitness or even mortality, Acidosis, hypovolemic shock and organ dysfunction Short Name	5	Tissue	Nov 29, 2016	Dec 3, 2016	187: Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage
1134	Irreversible inhibition of hepatic VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone Short Name	3	Molecular	Nov 29, 2016	Dec 3, 2016	187: Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage
1133	Hemostasis, Depletion from blood of fully functional carboxylated clotting factors Short Name	2	Tissue	Nov 29, 2016	Dec 3, 2016	187: Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage
1132	Blood loss and development of anemia, Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal Short Name	3	Cellular	Nov 29, 2016	Dec 3, 2016	187: Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage
1131	Failure in gamma-glutamyl carboxylation of clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) Short Name	4	Molecular	Nov 29, 2016	Dec 3, 2016	187: Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage
1130	Failure in vascular repair mechanisms, Unresolved blood loss (hemorrhage) Short Name	2	Organ	Nov 29, 2016	Sep 16, 2017	187: Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage
1129	Unresolved blood loss (hemorrhage), Failure in vascular repair mechanisms Short Name	0		Nov 29, 2016	Nov 29, 2016	None
1128	Unresolved hemorrhage, Failure in vascular repair mechanisms Short Name	0		Nov 29, 2016	Nov 29, 2016	None
1127	Anemia, Impaired oxygen and nutrient delivery to tissue, impaired carbon dioxide and waste product removal Short Name	0		Nov 29, 2016	Nov 29, 2016	None
1126	Unresolved blood loss, Failure in vascular repair mechanisms Short Name	0		Nov 29, 2016	Nov 29, 2016	None
1125	Impaired oxygen and nutrient delivery to tissue, impaired removal of carbon dioxide and other waste products, Hemorrhage, organ dysfunction and hypovolemic shock Short Name	0		Nov 29, 2016	Nov 29, 2016	None
1124	Hemorrhage , Impaired oxygen delivery and nutrient delivery to tissue, impaired carbon dioxide and waste product removal Short Name	0		Nov 29, 2016	Nov 29, 2016	None
1123	Hemorrhage, organ dysfunction, hypovolemic shock, Impaired oxygen delivery to tissue Short Name	0		Nov 29, 2016	Nov 29, 2016	None
1122	Under carboxylated clotting factors will not assemble on cell surfaces to form clot, Failure of secondary hemostasis Short Name	1	Tissue	Nov 29, 2016	Dec 3, 2016	187: Anticoagulant rodenticide inhibition of vitamin K epoxide reductase resulting coagulopathy and hemorrhage
1121	Hemorrhage , organ dysfunction, hypovolemic shock Short Name	0		Nov 29, 2016	Nov 29, 2016	None
1120	Under carboxylated clotting factors will not assemble on cell surfaces , Failure to form clot Short Name	0		Nov 29, 2016	Nov 29, 2016	None
1119	Failure in gamma-glutamyl carboxylation of glutamine residues on clotting factors II, VII, IX and X, Under carboxylation of clotting factors (e.g., des-gamma-carboxy prothrombin) Short Name	0		Nov 29, 2016	Nov 29, 2016	None
1118	Irreversible inhibition of VKOR by binding of AR at tyrosine 139, Failure to cycle vitamin K epoxide to vitamin K to form vitamin K hydroquinone Short Name	0		Nov 29, 2016	Nov 29, 2016	None
1117	Irreversible inhibition of VKOR by binding at tyrosine 139, Short Name	0		Nov 29, 2016	Nov 29, 2016	None
1116	Decreased, Triiodothyronine (T3) in tissues Short Name	2	Tissue	Nov 29, 2016	Sep 1, 2020	2 AOPs 189: Type I iodothyronine deiodinase (DIO1) inhibition leading to altered amphibian metamorphosis 190: Type II iodothyronine deiodinase (DIO2) inhibition leading to altered amphibian metamorphosis
1115	Increase, Reactive oxygen species Short Name Increase, ROS	1	Cellular	Nov 29, 2016	Jun 12, 2025	62 AOPs 186: unknown MIE leading to renal failure and mortality 213: Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) 303: Frustrated phagocytosis-induced lung cancer 383: Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis 382: Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis 384: Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease 396: Deposition of ionizing energy leads to population decline via impaired meiosis 409: Frustrated phagocytosis leads to malignant mesothelioma 413: Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure 416: Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway 418: Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway 386: Deposition of ionizing energy leading to population decline via inhibition of photosynthesis 387: Deposition of ionising energy leading to population decline via mitochondrial dysfunction 319: Binding to ACE2 leading to lung fibrosis 451: Interaction with lung resident cell membrane components leads to lung cancer 476: Adverse Outcome Pathways diagram related to PBDEs associated male reproductive toxicity 492: Glutathione conjugation leading to reproductive dysfunction via oxidative stress 497: ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome 500: Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis 505: Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway 513: Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway 521: Essential element imbalance leads to reproductive failure via oxidative stress 540: Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production 462: Activation of reactive oxygen species leading the atherosclerosis 299: Deposition of energy leading to population decline via DNA oxidation and follicular atresia 311: Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis 332: Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell growth 331: Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death 326: Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation and reduced cell proliferation 333: Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation 327: Excessive reactive oxygen species production leading to mortality (1) 328: Excessive reactive oxygen species production leading to mortality (2) 329: Excessive reactive oxygen species production leading to mortality (3) 330: Excessive reactive oxygen species production leading to mortality (4) 26: Calcium-mediated neuronal ROS production and energy imbalance 534: Succinate dehydrogenase (SDH) inhibition leads to oxidative stress 273: Mitochondrial complex inhibition leading to liver injury 488: Increased reactive oxygen species production leading to decreased cognitive function 298: Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer 27: Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) 511: The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects 207: NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans 423: Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway 481: AOPs of amorphous silica nanoparticles: ROS-mediated oxidative stress increased respiratory dysfunction and diseases. 282: Adverse outcome pathway on photochemical toxicity initiated by light exposure 569: Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway 324: Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation and cell death 325: Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation and reduced cell growth 595: Emerging OPFRS reproductive outcome pathway 596: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell injury/death 598: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and reduced cell proliferation 599: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and cell injury/death 600: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell growth 601: Excessive reactive oxygen species leading to growth inhibition via fatty acid oxidation and reduced cell proliferation 602: Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage 603: Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell cycle disruption 608: Thyroid Hormone Excess Leading to Reduced, Swimming Performance via Hypomyelination 613: Peroxisome proliferator-activated receptor alpha activation leading to early life stage mortality via increased reactive oxygen species production 622: Calcineurin inhibitor induced nephrotoxicity leading to kidney failure 636: Increase in reactive oxygen species (ROS) leading to human amyotrophic lateral sclerosis (ALS) 638: Co-exposure to microplastics and cadmium leading to progression from NAFLD to liver tumorigenesis 472: DNA adduct formation leading to kidney failure